News from jhl biotech A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 27, 2018, 15:00 ET JHL Biotech Announces First Patient Randomized in the Phase III Study of JHL1101 to Treat Diffuse Large B-Cell Lymphoma

JHL Biotech announced today that the first patient at Beijing Cancer Hospital has been successfully randomized in the Phase III study of JHL1101 to...


Oct 16, 2018, 15:22 ET UPDATED-- JHL Biotech Announces China Approves Phase I and Phase III Clinical Trial Application for Bevacizumab Biosimilar to Treat Cancer

JHL Biotech announced that the National Medical Products Administration of the PRC (NMPA) has approved JHL's Phase I and Phase III Clinical Trial...


Aug 09, 2018, 21:24 ET JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Trastuzumab Biosimilar to Treat Breast Cancer

JHL Biotech has announced it received a positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European...


Aug 09, 2018, 21:24 ET JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Bevacizumab Biosimilar to Treat Lung Cancer

JHL Biotech has announced it received a positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European...


Jul 09, 2018, 13:30 ET JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Rituximab Biosimilar

JHL Biotech has announced it received a positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European...


Jul 05, 2018, 17:05 ET JHL Biotech Announces China Approves Clinical Trial Rituximab Biosimilar to Treat Non-Hodgkin Lymphoma

JHL Biotech announced today that the Center for Drug Evaluation (CDE), State Drug Administration of China (SDA) has approved JHL's Phase I and Phase...


Jun 13, 2018, 04:25 ET JHL Biotech Announces Completion of Convertible Bond Issuance and Appointment of New Chief Financial Officer

JHL Biotech has raised US$106 million in a convertible bond issuance, which closed May 15, 2018. Proceeds raised from the issuance will be used for...


Dec 20, 2017, 12:29 ET JHL Biotech Submits Clinical Trial Application in Europe for Proposed Dornase Alfa Biosimilar to Affordably Manage Symptoms of Cystic Fibrosis

JHL Biotech (Stock Code: 6540.TWO) announced today that it has submitted a Phase 1 Clinical Trial Application to the Dutch Healthcare Authority for...


Dec 20, 2017, 09:17 ET JHL Biotech Submits Clinical Trial Application in Europe for Proposed Bevacizumab Biosimilar to Treat Colorectal, Lung, and Ovarian Cancers

JHL Biotech Inc. (Stock Code: 6540.TWO) announced that it submitted a Phase I Clinical Trial Application on December 15, 2017 to European authorities ...


Mar 29, 2017, 06:52 ET Первый пациент получает дозу препарата в рамках европейского исследования Фазы I JHL1101 компании JHL

Компания JHL Biotech Inc. (код акций на фондовой бирже: 6540.TWO) сегодня сообщила о введении первой дозы лекарства пациенту в клиническом испытании...


Mar 29, 2017, 03:05 ET JHL Doses First Patient In JHL1101 Phase I European Trial

JHL Biotech Inc. (Stock Code: 6540.TWO) today announced that the first patient has been dosed in the company's Phase I clinical trial of JHL1101 (a...


Oct 20, 2015, 04:00 ET JHL Biotech Appoints New Leaders to Management Team

JHL Biotech (TWEM: 6540), an emerging biosimilars company in Taiwan and China, announced today that Max Chan will join the company as Chief Financial ...


Oct 02, 2015, 01:26 ET JHL Biotech Lists on the Taiwan Emerging Stock Board

JHL Biotech (TWEM: 6540), an emerging biosimilars company incorporated in Cayman Islands and based in Taiwan and China, announced today it has been...


Sep 28, 2015, 01:48 ET CORRECTED--JHL Biotech Hosts Prominent Brazilian Delegation in Taiwan to Advance Biosimilar Collaborations--CORRECTED

JHL Biotech, an emerging biosimilars company in Taiwan, hosted a delegation of Brazilian government officials and top-ranking biotech executives who...


Sep 18, 2015, 02:00 ET JHL Biotech Hosts Prominent Brazilian Delegation in Taiwan to Advance Biosimilar Collaborations

JHL Biotech, an emerging biosimilars company in Taiwan, hosted a delegation of Brazilian government officials and top-ranking biotech executives who...


May 11, 2015, 09:37 ET JHL Biotech Successfully Raises US$45.6 Million Series C Financing

JHL Biotech, Inc., an emerging biopharmaceutical company, today announced that it has closed a Series C fundraising of $45.6 million, led by funds...